| Document |
Document Title |
|
WO/2022/096499A1 |
A chromatographic method for separation of lipid-membrane-enclosed compound assemblages (LMCAs) from chromatin heteroaggregates including degraded remnants from LMCAs in a sample, - contacting the sample with a chromatographic material w...
|
|
WO/2022/098595A1 |
Described herein are materials and methods for protein production and analysis.
|
|
WO/2022/099162A1 |
Automated systems and methods for low-pH viral inactivation include adding an elution pool to a first vessel with an acid. Once first vessel pH probes measure sufficiently low pH, the pool is transferred to a second vessel, where the pH ...
|
|
WO/2022/097540A1 |
The present invention addresses the problem of a desired elongation reaction not progressing as a result of a 6-membered cyclic amidine skeleton structure and a diketopiperazine formed when removing an N-terminated protective group durin...
|
|
WO/2022/095698A1 |
Disclosed are an antibody capable of binding to human CD38, a preparation method therefor and an application thereof. The antibody of the present invention comprises anti-human CD38 antibodies having high, medium, and low affinities, can...
|
|
WO/2022/098247A1 |
The present invention relates to products and processes for the treatment or prevention of viral infection(s). In particular the invention relates to the use of one or more proteins, typically obtained from milk, for the treatment or pre...
|
|
WO/2022/097500A1 |
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
|
|
WO/2022/094095A1 |
Disclosed herein are methods, reagents and devices for the rapid detection of SARS- CoV-2 nucleocapsid antigens in clinical samples using high throughput methods.
|
|
WO/2022/090520A1 |
The present invention concerns a method for site-selective modification of a target protein or peptide by use of an acylation tag comprising a single lysine residue and at least three histidine residues. Upon contact with an acylating re...
|
|
WO/2022/092301A1 |
This cyclooctin derivative and salt thereof are represented in formula (1). (In the formula, X represents -CHR6-, -NR7- or -O-; L represents a linker group; in the case of not being a linker group, R1-R7 independently represent a hydroge...
|
|
WO/2022/094340A1 |
The present disclosure relates to dosage regimens of complement factor H (CFH) protein for treating patients having inflammatory ocular diseases or conditions (e.g., age-related macular degeneration or early-onset macular dystrophies). T...
|
|
WO/2022/088291A1 |
Provided are a group transfer method for the selective modification of a target protein and the use thereof. According to the group transfer method for the selective modification of a target protein, a target protein is modified efficien...
|
|
WO/2022/094116A1 |
The present disclosure provides purification platforms comprising a depth filter step and/or a hydrophobic interaction chromatography (HIC) step and/or a MM-HIC/ IEX chromatography step, and are useful for providing a method of reducing ...
|
|
WO/2022/087669A1 |
Described herein are fusion peptides comprising (i) a peptide sequence comprising the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:24 or a fragment or derivative thereof, or a sequence at least about 80% identical thereto and (ii) an ...
|
|
WO/2022/088220A1 |
Provided are a polymethyl methacrylate (PMMA) matrix-based Protein A affinity chromatography medium and preparation method and application thereof. Comprised are the following steps: performing hydrophilization of polymethyl methacrylate...
|
|
WO/2022/084441A1 |
A method and apparatus for conducting chemical reactions under controlled conditions, where one compound is in stochiometric excess over the other, using membrane filtration.
|
|
WO/2022/084362A1 |
The present invention relates to a method, a diagnostic system, a kit and the use thereof for efficiently detection of an analyte of interest by nanoESI mass spectrometry.
|
|
WO/2022/079492A1 |
Devices and methods for portable, modular production of a biological material comprising a device compatible with receiving one or more cartridges, wherein production and purification of the biological material are handled inside the car...
|
|
WO/2022/079127A1 |
The present invention relates to a method for covalently binding a first agent and a second agent, the first agent comprising a first recognition element, wherein the first recognition element comprises an 1,4-dioxo moiety having a struc...
|
|
WO/2020/210535A9 |
The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with add...
|
|
WO/2022/080481A1 |
A problem addressed by the present invention is to provide complexes having greater stability than in the past without harming drug efficacy. The complexes of the present invention are complexes of a chelating agent and an anti-HER2 anti...
|
|
WO/2022/081957A1 |
Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles (WAEVs) for presenting HIV antigen domains. These WAEVs can be harnessed to deliver and present HIV an...
|
|
WO/2022/078976A1 |
The present invention relates to a method for purifying cationic protein fractions by endotoxin removal, and also to the purified fractions thus obtained.
|
|
WO/2022/081895A1 |
Disclosed herein are glycoconjugates having a cell-binding agent, such as an antibody, conjugating to a payload, such as a drug. The drug is conjugated to the cell-binding agent through an oligosaccharide linker. The glycoconjugates conj...
|
|
WO/2022/082201A1 |
Provided herein are antibodies that bind to cleaved inflammatory caspase (iCaspase) substrates and methods of screening for such antibodies. Also provided herein are detection methods using such antibodies for detecting a cleaved iCaspas...
|
|
WO/2022/081775A1 |
Provided herein are affinity ligands that specifically interact with AAV8 capsid and/or AAV8 variant capsid, affinity agents comprising the affinity ligands, and methods of their use for binding, isolation, and/or purification of AAV8 an...
|
|
WO/2022/081911A1 |
Various embodiments provide a homo-bivalent linker compound comprising identical functional groups at either end, methods of making such linker compounds, and methods of using the linker compounds.
|
|
WO/2022/080385A1 |
The present disclosure relates to: a peptide with which at least one molecule of a group shown below is conjugated and which has a length of 13 to 19 amino acid residues; and a method for modifying an antibody with the peptide.
|
|
WO/2022/076318A1 |
Provided herein are optimized methods for concentrating large volumes of antibody feedstocks to generate concentrated drug substances by ultrafiltration in a batch-like mode using a fed-batch setup.
|
|
WO/2022/073066A1 |
The present application relates to infectious diseases, pathogenic organisms or pathogenic antigens, and the immune responses that are the body's first line of defense thereto. The application enables medical protocols and products inter...
|
|
WO/2022/074397A1 |
Provided herein is a method of chemically modifying a polypeptide or polynucleotide monomer. The monomer may be a monomer of a protein pore such as a monomeric or oligomeric protein pore. Also disclosed are related monomers and oligomers...
|
|
WO/2022/072934A1 |
The present disclosure relates to methods for reducing host cell protein content in antibody preparation recombinantly produced in a host cell in the manufacturing process of antibodies intended for administration to a patient. The discl...
|
|
WO/2022/071990A1 |
Compositions and methods are provided that simplify isolation of proteins of interest from serum or plasma. Finely divided silica or a similar lipid/lipoprotein binding solid is used in combination with a protein precipitating agent to g...
|
|
WO/2022/072919A1 |
The present disclosure relates to methods for reducing host cell protein content in a protein preparation recombinantly produced in a host cell in the manufacturing process of proteins intended for administration to a patient.
|
|
WO/2022/067879A1 |
Provided in the present invention is a protein synthesized by means of a chemical pathway or genetic engineering, wherein the protein has a functional domain that is capable of binding to a capsid protein of a virus that can cause diarrh...
|
|
WO/2022/069903A1 |
A method for producing β-trypsin, the method comprising: a) renaturing denatured trypsinogen, thereby producing renatured trypsinogen, wherein the renaturing is carried out in a buffer that comprises L-arginine; b) purifying the renatur...
|
|
WO/2022/072899A1 |
The present application provides methods and systems for viral clearance for purifying an antibody from a sample comprising one or more impurities including viral particles. The method is conducted in a system which includes a hydrophobi...
|
|
WO/2022/068141A1 |
Provided is a humanized anti-CD22 recombinant immunotoxin, which has reduced immunogenicity and maintains the CD22 binding affinity and corresponding biological activity before humanization transformation, and is used for preparing a dru...
|
|
WO/2022/068784A1 |
Provided are a selenium-rich Cordyceps militaris derived active selenium peptide with a neuron protection function, and a preparation method therefor and the use thereof. The amino acid sequence of the selenium-rich Cordyceps militaris d...
|
|
WO/2022/069945A1 |
The present invention provides a method of fractionating human plasma, in some embodiments, using the Cohn fractionation procedure. The improvement comprises the use of physiologically active reconstituted spray dried human plasma as the...
|
|
WO/2022/071521A1 |
The purpose of the present invention is to provide a crosslinking peptide that can interact with a target protein, a method for producing said crosslinking peptide, and a pharmaceutical composition having said crosslinking peptide as an ...
|
|
WO/2022/066010A1 |
The invention relates a method, an electrocoagulation device, and a use of said device for electrocoagulation of proteins from leaf juice. The method comprises the steps of: - providing a device for electrocoagulation, comprising: - a re...
|
|
WO/2022/064023A1 |
The present disclosure relates to methods of releasing a target molecule from intein complexes comprising an intein-C tagged target molecule and intein-N polypeptides, by contacting the intein complexes with nitrogen containing heteroaro...
|
|
WO/2022/063770A1 |
The present invention relates to a method for recovering a protein of interest from a bacterial fermentation broth, wherein the bacterial cells in the fermentation broth exhibit a high degree of lysis, comprising the steps of adding to t...
|
|
WO/2022/064500A1 |
Provided herein a method for forming one or more intramolecular disulfide bonds.
|
|
WO/2022/061214A1 |
The present disclosure provides methods for purifying multispecific antibodies from a mispaired variant thereof by performing a multi-mode chromatography.
|
|
WO/2022/060535A1 |
The present embodiments relate to pathogen clearance. Subject matter of the present embodiments are computer-implemented methods, computer systems and computer-readable storage media for predicting the performance of pathogen clearance p...
|
|
WO/2022/055269A1 |
The present invention relates to a method for preparing atelocollagen and a use thereof and, more particularly, to a method for removing an immunogen from pig skin-derived collagen and preparing atelocollagen in high purity and high yiel...
|
|
WO/2022/056466A1 |
Provided herein are, inter alia, biological manufacturing and downstream purification processes.
|
|
WO/2022/051963A1 |
A method for preparing plecanatide. The method comprises the following steps: 1) coupling a Y resin with X, Linker and Fmoc-Leu-OH, respectively, to obtain a Fmoc-Leu-Linker-X-Y resin, wherein X is selected from an amino acid or Pro havi...
|
